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Abstract
Background:  Methionine aminopeptidase is a potential target of future antibacterial and
anticancer drugs. Structural analysis of complexes of the enzyme with its inhibitors provides
valuable information for structure-based drug design efforts.
Results: Five new X-ray structures of such enzyme-inhibitor complexes were obtained. Analysis
of these and other three similar structures reveals the adaptability of a surface-exposed loop
bearing Y62, H63, G64 and Y65 (the YHGY loop) that is an integral part of the substrate and
inhibitor binding pocket. This adaptability is important for accommodating inhibitors with variations
in size. When compared with the human isozymes, this loop either becomes buried in the human
type I enzyme due to an N-terminal extension that covers its position or is replaced by a unique
insert in the human type II enzyme.
Conclusion: The adaptability of the YHGY loop in E. coli methionine aminopeptidase, and likely in
other bacterial methionine aminopeptidases, enables the enzyme active pocket to accommodate
inhibitors of differing size. The differences in this adaptable loop between the bacterial and human
methionine aminopeptidases is a structural feature that can be exploited to design inhibitors of
bacterial methionine aminopeptidases as therapeutic agents with minimal inhibition of the
corresponding human enzymes.
Background
Methionine aminopeptidase (MetAP) removes the N-ter-
minal methionine residue from nascent proteins in all
types of cells [1]. Prokaryotic cells express only one
MetAP, and its essentiality was demonstrated by the
lethality of its deletion from Escherichia coli [2] and Salmo-
nella typhimurium [3]. MetAP is therefore a potential target
for developing novel broad spectrum antibacterial drugs
[4]. Eukaryotic cells have two types of MetAP (type I and
type II), and deletion of both MetAP genes in Saccharomy-
ces cerevisiae was shown to be lethal [5,6]. Fumagillin and
its analogues TNP-470 and ovalicin are potent antiang-
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iogenic compounds and are also selective inhibitors of
human type II MetAP [7-9]. The antiproliferative benga-
mides inhibit both types of human MetAP [10]. Therefore,
human MetAPs may also serve as targets for development
of new anticancer therapeutics.
Early MetAP inhibitors were derived from peptide sub-
strates or the cleavage product methionine, such as the
peptic inhibitor (3R)-amino-(2S)-hydroxyheptanoyl-L-
Ala-L-Leu-L-Val-L-Phe-OMe (Ki 5 μM) [11] and norleu-
cine phosphonate (NleP) [12]. Both are considered as
transition state inhibitors. Although these compounds are
not desired as therapeutic agents, structural studies of
their complexes with MetAP have provided valuable
insight of the catalysis and inhibition of MetAP [12-14].
Fumagillin, a natural product, and its analogues are a
unique class of MetAP inhibitors that covalently modify a
conserved histidine residue at the active site (H79 of E. coli
MetAP, and the equivalent H231 of human type II MetAP)
[9,15,16]. Several classes of non-peptidic and reversible
MetAP inhibitors have been identified recently, such as
furancarboxylic acids [17,18], thiabendazole and other
thiazole-containing compounds [17,19-21], triazole-
based derivatives [22-24], and sulfonamides [25,26].
However, structural analysis of these nonpeptidic inhibi-
tors in complex with MetAP showed that inhibition by
many of the thiazole and triazole-containing compounds
and sulfonamides is metal-mediated, and they bind to the
active site of enzyme through a divalent metal ion with
one of the conserved active site histidines (most with
H97, and some with H181; both are E. coli MetAP num-
bering) [19,21,25]. It has been pointed out that formation
of such complexes may be an artefact during crystalliza-
tion or in in vitro assays using high metal concentrations
[14,19,27], and whether there are enough free metal ions
available inside cells to form such inhibitor-enzyme com-
plexes is a question.
MetAP was initially characterized as a Co(II) enzyme
because of reproducible activation of the apoenzyme by
Co(II) [5,28]. Many X-ray structures of MetAPs with or
without a ligand bound [29] show a dinuclear metal site
inside the active site pocket that has five conserved resi-
dues D97, D108, H171, E204 and E235 (E. coli MetAP
numbering) as metal ligands and filled with two Co(II)
ions. The metal ion used to form the inhibitor-enzyme
complexes mentioned above is neither of the metal ions,
but an additional one close to the dinuclear site. In addi-
tion to Co(II), other divalent metals such as Mn(II),
Ni(II), Zn(II), and Fe(II) have been shown to activate the
enzyme in vitro as well [30,31]. It is not known which of
the metal ions is actually used by MetAP under physiolog-
ical conditions, but speculation favors Fe(II), Zn(II) or
Mn(II) for this role [23,31,32].
By high throughput screening of a diverse chemical library
of small organic compounds, we have discovered furan-
carboxylic acids as MetAP inhibitors with high selectivity
for the Mn(II)-form of the enzyme [17]. Importantly, they
remain potent as MetAP inhibitors at low and physiolog-
ically more relevant metal concentration [27]. X-ray struc-
tures showed that they directly interact with the two
metals at the dinuclear site without requiring the addi-
tional metal for binding [17,33]. Several derivatives of the
screening hits were synthesized to study structure-func-
tion relationships for their inhibitory potency and metal-
loform-selectivity [18]. To elucidate the chemical basis for
metalloform-selective MetAP inhibition in greater detail,
we have now carried out structural studies of E. coli MetAP
in complex with these metalloform-selective inhibitors.
We report here five new X-ray crystal structures of the
Mn(II)-form of E. coli MetAP, each complexed with a dif-
ferent inhibitor (Fig. 1). Analysis of these and other com-
plexes identifies an adaptable loop of the active site
pocket as an important structural feature of the enzyme
Chemical structures of the inhibitors used in this study Figure 1
Chemical structures of the inhibitors used in this study. X-ray structures of E. coli MetAP complexed with 1–3 have been reported previously [17, 
33], and those with 4–8 are reported here. They are potent inhibitors of the Mn(II)-form of E. coli MetAP with IC50 values of 0.51, 0.69, 0.29, 1.1, 0.56, 
0.37, 1.6 and 1.2 μM, respectively [18].
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that may be exploited to achieve selective inhibition of
bacterial MetAP enzymes vs. mammalian counterparts.
Results and Discussion
Overall structure of E. coli MetAP in complex with the 
inhibitors
The crystals generated by hanging-drop method consist-
ently produced high-quality diffraction data for structural
solution to resolution from 1.6 to 1.9 Å (Table 1). All
eight structures, including the five new ones, have the typ-
ical "pita-bread" fold (Fig. 2A) found in other MetAP
structures [29], and each of them contains two Mn(II)
ions at the dinuclear metal site. A single molecule of
inhibitor sits in the shallow active site pocket (Fig. 2B). A
surface-exposed loop containing Y62, H63, G64 and Y65
(the YHGY loop) is an integral part of the active site
pocket. Notably, this loop adapts different positions in
these structures to accommodate different inhibitors, and
the implications of this adaptability for inhibitor design
will be discussed further below.
Binding of the inhibitors to E. coli MetAP
Common features of the Mn(II)-form selective inhibitors
4–8 bound to E. coli MetAP in the five new structures are
that all use their carboxylate group to coordinate with the
two Mn(II) ions at the dinuclear metal site and all take a
non-coplanar or twisted conformation for the two aro-
matic rings (Fig. 3), consistent with our previously
reported structures of E. coli MetAP complexed with 1–3
[17]. The twisted conformation found in all of the Mn(II)-
form-selective inhibitors 1–8  is in agreement with the
requirement of a hydrophobic ortho-substitution, such as
chlorine, on the phenyl ring for inhibitory activity
[17,18]. This twisting is usually explained in terms of
repulsion between ortho hydrogens or substituents in a
planar conformation. The twist angles observed in the
MetAP complexes of 1–8 range from the smallest 23.3°
for 6 to the largest 52.9° for 4, suggesting that in general,
the phenylfuran-based inhibitors dock into the active site
in a conformation that may correspond to a minimum-
energy solution conformation. This in turn would
enhance their binding by decreasing the fraction of bind-
ing energy that would be "wasted" to distort the molecule
to a less-favorable conformation in the bound state.
Adaptability of the YHGY loop in the inhibitor binding 
pocket
With the eight structures with similar inhibitors 1–8 avail-
able, we aligned these structures to identify similarities, as
well as differences, among them. All structures aligned
well with root mean square deviations (rmsd) ranging
from 0.112 to 0.356 Å for the Cα carbons of residues
4–256 (Table 2). With this level of overall similarity, it is
very noticeable that some residues are essentially immo-
bile while others occupy distinctly different positions
when different inhibitors are bound (Fig. 4). The residues
forming the dinuclear metal site (H171, D108, E204,
E235 and D97), as well as the nearby residues S110, T202,
F177, H178 and H79, show little change in position upon
binding of any of these inhibitors. In contrast, residues
Y62, H63, G64, and Y65 in the YHGY loop, as well as res-
idue W221, moved significantly. The largest changes
occur between complexes containing inhibitors 1 and 8,
where the respective Cα carbons of residues Y62, H63,
G64 and Y65 differ in positions by 1.00, 1.58, 1.62 and
1.36 Å, respectively. The rmsd value for all Cα carbons of
residues 4–256 is also the largest at 0.356 Å between the
two structures. Clearly, the loop is pushed outwards to
Overall structure of E. coli MetAP complexed with an inhibitor Figure 2
Overall structure of E. coli MetAP complexed with an inhibitor. Ribbon (A) and surface (B) drawings are shown for one of the structures with 
inhibitor 4 situated at the active site. The two Mn(II) ions are shown as green spheres, and the inhibitor is shown as sticks (yellow, carbon; red, oxygen; 
and blue, nitrogen). In ribbon drawing, the secondary structures are coded as red for α-helices, yellow for β-sheets, and green for loops and other struc-
tures. The YHGY loop (Y62, H63, G64 and Y65) is indicated by a red arrow.BMC Structural Biology 2007, 7:84 http://www.biomedcentral.com/1472-6807/7/84
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accommodate the extra volume occupied by inhibitor 8,
and the surface exposure of the loop allows it to more
readily accommodate the inhibitor. The same is true for
other inhibitors, and the loop show a great adaptability.
This flexibility allows the binding pocket to adapt to dif-
ferent shapes of the bound inhibitors. In principle, there
could be an energetic penalty to pay (in terms of weaker
binding) for moving this loop. However, the fact that
inhibitors 1–8 are roughly equipotent [18] suggests that
any energetic penalty for moving the loop may be com-
pensated by other favorable interactions, such as compen-
sating desolvation effects.
Statistical analysis of the loop adaptability
The YHGY loop (Y62, H63, G64, and Y65) forms part of
the substrate and inhibitor binding pocket and has direct
contact with the bound inhibitors. Positional uncertainty
of these atoms in the structures is reflected in their B-fac-
tors. The B-factor values of atoms in this loop refined to
high values in some of the structures (2EVM, 2EVC, 2Q92,
2Q94), indicating that these atoms are not as well ordered
in those structures as in others (Fig. 5). However, the same
atoms in some of the structures (2Q93, 2Q96) have low
B-factors. The atoms in the YHGY loop do not consistently
show high value for B-factors in the presence of a bound
inhibitor, in comparison with other parts of the molecule.
One of the reasons for this observation is that the value of
B-factor is affected by interactions of the atom with the
bound inhibitor. Therefore, the absolute value of their B-
factors is not a good indicator of their adaptability.
Although the eight structures show good overall align-
ment as indicated by their small rmsd values during pair-
wise comparisons (Table 2), the YHGY loop assumes dif-
ferent positions when different inhibitors are present (Fig.
4). It is revealing that when the residues 61–64 (the YHGY
loop) are excluded from the rmsd calculation, the values
dropped significantly for some of the pairs (Table 2), indi-
cating a major contribution of the YHGY loop to the rmsd
values for these pairs. Notably, the rmsd value between
1XNZ (complex with 1) and 2Q96 (complex with 8)
showed the biggest drop from 0.356 Å to 0.304 Å with a
reduction of 0.051 Å (14%) just by removing four out of
253 residues for the rmsd calculation.
To further assess the differences among the eight complex
structures, we performed pair-wise comparisons using
Cruickshank's diffraction precision index [34] with the
addition of linear B-factor scaling as implemented in the
program ESCET [35,36]. The Cα carbons of residues
4–256 were used in calculating error-scaled difference dis-
tance matrices (Fig. 6). When the lower limit was set at the
Table 1: X-ray data collection and refinement statistics
Inhibitor 45678
Inhibitor code B23 B21 A04 A05 B18
PDB code 2Q92 2Q93 2Q94 2Q95 2Q96
Cell Parameters
Space group P21 P21 P21 P21 P21
a (Å) 38.1 39.1 38.2 38.8 39.3
b (Å) 61.0 62.3 60.6 62.4 62.0
c (Å) 50.7 52.4 50.6 52.4 52.4
β (deg) 104.9 108.8 104.8 108.4 108.8
X-ray Data Collection
Resolution range (Å)
Overall 30-1.9 20-1.6 20-1.6 24-1.7 20-1.6
Outer shell 2.0-1.9 1.7-1.6 1.7-1.6 1.8-1.7 1.7-1.6
Collected reflections 63,846 108,452 100,161 93,908 112,816
Unique reflections 17,799 29,294 27,719 26,219 31,502
Completeness (%) a 100 (100) 93 (89) 99 (98) 100 (100) 100 (100)
I/σ (I)a 18.1 (4.7) 23.6 (11.1) 20.8 (2.5) 17.3 (2.8) 23.5 (7.2)
Rmerge (%) a 5.4 (22.1) 3.0 (9.9) 4.4 (36.3) 5.5 (38.9) 3.8 (13.8)
Refinement Statistics
R (%) 20.3 22.6 21.3 21.4 21.1
Rfree (%) 23.8 25.1 23.8 23.9 23.5
RMSD bonds (Å) 0.006 0.005 0.005 0.005 0.004
RMSD angles (deg) 1.32 1.32 1.32 1.33 1.30
No. of solvent molecules 133 224 194 195 234
<B> enzyme (Å 2) 21.4 11.3 20.9 19.0 11.8
<B> inhibitor (Å 2) 25.8 13.3 18.4 16.3 12.1
<B> water (Å 2) 27.0 18.6 28.9 25.8 18.8
a Numbers given in parentheses corresponding to the outer shell of data.BMC Structural Biology 2007, 7:84 http://www.biomedcentral.com/1472-6807/7/84
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Binding modes of the inhibitors at the active site of E. coli MetAP Figure 3
Binding modes of the inhibitors at the active site of E. coli MetAP. In the stereo views, only five conserved residues that coordinate with Mn(II) 
ions (D97, D108, H171, E204, E235) and two conserved histdines (H79, H178) are shown. The bound inhibitors are 4 (A), 5 (B), 6 (C), 7 (D), and 8 (E), 
respectively. The colour scheme is as follows: gray, carbon (protein residues); yellow, carbon (inhibitor); blue, nitrogen; red, oxygen; green, chlorine; and 
cyan, fluorine. Mn(II) ions are shown as green spheres. SigmaA-weighted Fobs-Fcalc standard omit maps (inhibitor and metal ions were not included in the 
model for the structure-factor calculation) are shown superimposed on the refined structures as blue meshes contoured at 3.5 standard deviations of the 
resulting electron density map.BMC Structural Biology 2007, 7:84 http://www.biomedcentral.com/1472-6807/7/84
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4σ level (where σ is the uncertainty in the measurement
of the difference), the only region that was found to be
flexible was residues 61–67. If the limit was raised to 5σ,
the flexible region narrowed to residues 62–66. The error-
scaled difference distance matrices calculated by ESCET
are consistent with the rmsd values presented in Table 2.
This analysis confirms that the YHGY loop (residues
61–64) shows greater flexibility than other parts of the
molecule in response to differing active site ligands.
Comparison with the structures of human type I and type 
II MetAPs
We observed previously that some inhibitors of E. coli
MetAP inhibit only human type I MetAP that is truncated
at the N-terminus but not the full-length enzyme with an
intact N-terminus [37]. As structures of both type I and
type II human MetAPs are available, we aligned the struc-
ture of E. coli MetAP with those of the two human sub-
types.  E. coli MetAP is a typical bacterial MetAP,
containing only a catalytic domain (Fig. 7C). On the other
hand, mammalian MetAPs, including both type I and type
II human MetAPs, have an N-terminal extension. Type II
human MetAP has an extra insert, dissecting the catalytic
domain into two fragments.
By overlaying the structures of E. coli MetAP and human
type I MetAP, we see that the N-terminal extension of the
human enzyme wraps around the enzyme surface and
covers the YHGY loop (Fig. 7A). The surface-exposed loop
in E. coli MetAP now becomes mostly buried in human
type I enzyme. This could greatly reduce the plasticity of
the loop and make the inhibitor binding pocket much less
tolerant to structural variations in inhibitor molecules.
This change is consistent with our previous observation
on inhibition of the truncated and full length human type
I MetAPs [37], and the partially buried nature of the loop
Adaptability of residues to the bound inhibitors at the active site Figure 4
Adaptability of residues to the bound inhibitors at the active site. In this stereo view, all eight structures, each with an inhibitor (1–8) bound, 
were superimposed. The inhibitors are shown as thick sticks, and the nearby protein residues are shown as thin sticks. The two Mn(II) ions are shown as 
spheres and labelled as Mn1 and Mn2. The YHGY loop and residues Y62, H63, Y65 and W221, as well as Mn(II) ions, of each structure are coloured the 
same as the corresponding inhibitor: 1, yellow; 2, green; 3, cyan; 4, black; 5, magenta; 6, blue; 7, grey; and 8, red.
Table 2: rmsd values generated by pair-wise comparisons of the eight complex structuresa
2EVM 2EVC 2Q92 2Q93 2Q94 2Q95 2Q96
1XNZ 0.161 (0.006) 0.140 (0.005) 0.231 (0.007) 0.333 (0.036) 0.254 (0.020) 0.316 (0.028) 0.356 (0.051)
2EVM 0.128 (0.004) 0.175 (0.001) 0.292 (0.026) 0.185 (0.008) 0.283 (0.018) 0.309 (0.039)
2EVC 0.192 (0.004) 0.307 (0.029) 0.200 (0.015) 0.289 (0.020) 0.319 (0.043)
2Q92 0.230 (0.022) 0.122 (0.009) 0.216 (0.014) 0.252 (0.035)
2Q93 0.245 (0.017) 0.112 (0.002) 0.117 (0.005)
2Q94 0.240 (0.012) 0.241 (0.028)
2Q95 0.170 (0.009)
a The pdb codes and the bound inhibitors in the eight structures are: 1XNZ, 1; 2EVM, 2, 2EVC, 3; 2Q92, 4; 2Q93, 5; 2Q94, 6; 2Q95, 7; and 2Q96, 
8. These structures were aligned in a pair-wise fashion using the Cα carbons of residues 4–256; the resulting rmsd values (in Å) are presented. 
Numbers given in parentheses are reductions of rmsd (in Å) when the same calculations were carried out with exclusion of residues 61–64 (the 
YHGY loop).BMC Structural Biology 2007, 7:84 http://www.biomedcentral.com/1472-6807/7/84
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could make it less adaptable for the inhibitors of differing
size.
In addition, an overlaying of the E. coli MetAP and human
type II MetAP structures reveals that the YHGY loop is not
present at all in human type II MetAP, and instead, its
position is now occupied by an insert, unique to type II
MetAP (Fig. 4B). The insert of approximately 65 residues
forms a distinct globular domain and is an integral part of
the active site pocket. The adaptability of its binding
pocket may be analyzed when more complex structures
are available. However, differences in adaptability are
likely found because the YHGY loop is part of the pocket
in E. coli MetAP and it is substituted by the globular insert
in human type II MetAP. It is interesting to note that the
N-terminal extension of human type II enzyme is located
away from the active site.
Implications of the adaptability of the YHGY loop in 
developing MetAP inhibitors as antibiotics
Structure-based drug design takes advantage of the struc-
tural information of a medicinally important protein,
especially at the active site, to guide the design and devel-
opment of protein ligands to achieve desired potency and
selectivity. Bacterial MetAP enzymes are the simplest in
the MetAP family and contain only a catalytic domain.
Most bacterial MetAPs, with exception of achaeal
enzymes, belong to the type I MetAP family and are
homologs. E. coli MetAP, as a typical bacterial MetAP, has
high sequence homology with human type I MetAP
within the catalytic domain (121 out of 264 residues are
identical). It is certainly desirable to identify the differ-
ences between bacterial MetAPs and human counterparts
so that MetAP inhibitors as potential antibiotics will selec-
tively inhibit only bacterial MetAPs. The N-terminal
extension and the insert in human MetAPs are the extra
structural elements that can be potentially exploited to
design selective inhibitors for bacterial MetAPs.
As more X-ray structures of E. coli MetAP in complex with
inhibitors have become available, we now can compare
the structures and characterize the binding of different
inhibitors. Careful structural analysis of these structures
reveals the adaptability of the YHGY loop (Y62, H63, G64
and Y65) that accommodates inhibitors of differing size.
The adaptability of this loop in bacterial enzymes could
be an important structural feature to exploit because the
loop is partially occluded by the N-terminal extension in
human type I MetAP [38-42] and is replaced by an unique
insert in human type II MetAP [15]. Consequently, the
ability to adapt multiple conformations within this loop
of E. coli MetAP, and likely of other bacterial MetAPs, may
not exist in human MetAPs and could be utilized to steer
MetAP inhibitors towards selective inhibition of the bac-
terial enzymes.
This observation emphasizes the importance in consider-
ing the dynamics of ligand binding to enzymes in mode-
ling inhibitors into a binding site on a protein, especially
during the virtual screening of MetAP inhibitors. A rigid
active site would appear to be relatively intolerant of any-
thing but a nearly perfect fit or a slightly undersized lig-
and, but a flexible site would be more forgiving and
tolerant of a wider range of structures. Molecules that
might appear to fit poorly based on a rigid structure
model may in reality fit quite well because of loop move-
ment. Recognizing and utilizing this flexibility could be
beneficial, for example, for optimizing the potency and
selectivity of an inhibitor or fine-tuning its biopharma-
ceutical properties.
Conclusion
Structural analysis of the complexes of E. coli MetAP with
a series of related inhibitors reveals the ability of the sur-
face-exposed loop containing the sequence YHGY to
adapt multiple conformations to better complement the
structural features of bound ligands. This adaptable loop
likely exists in all bacterial MetAPs based on sequence
similarity and the surface-exposed nature of the loop.
However, this loop is partially buried by an N-terminal
extension in the human type I MetAP and substituted by
a globular insert in the human type II MetAP. The differ-
ence in ability of the substrate/inhibitor binding pocket to
adapt to a wide range of ligand sizes may distinguish bac-
terial MetAPs from human MetAPs and could be exploited
to design selective inhibitors of bacterial MetAPs.
Distribution of B factors over the residues of the complex  structures Figure 5
Distribution of B factors over the residues of the 
complex structures. Only B-factors for Cα carbons are 
shown.
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Methods
Preparation of the protein and compounds
The recombinant E. coli MetAP was purified as an apoen-
zyme [30]. Compounds 1–3,  6  and  7  were purchased
from ChemBridge (San Diego, CA) and characterized by
1H and 13C NMR and high resolution mass spectrometry.
Compounds 4, 5 and 8 were synthesized in our labora-
tory. Their inhibitory activities on the Co(II)-, Mn(II)-,
Ni(II)- and Fe(II)-forms of E. coli MetAP have been
described previously [17,18].
Crystallization Conditions
Initial crystallization conditions were determined using
Crystal Screen and Index HT kits in 96-well sitting-drop
plates (Hampton Research) at room temperature. Final
crystals of the enzyme-inhibitor complexes were obtained
Error-scaled difference distance matrices generated by pair-wise comparisons of the eight complex structures Figure 6
Error-scaled difference distance matrices generated by pair-wise comparisons of the eight complex structures. A. Error-scaled difference 
distance matrices from pair-wise comparisons of all eight structures using ESCET program. The pdb codes and the bound inhibitors in the eight structures 
are: 1XNZ, 1; 2EVM, 2, 2EVC, 3; 2Q92, 4; 2Q93, 5; 2Q94, 6; 2Q95, 7; and 2Q96, 8. All changes in distances smaller than the threshold 1σ are shown in 
grey; differences between this lower limit and an upper limit of 8σ are shown using a colour gradient where red stands for expansion and blue for contrac-
tion, light colours represent small changes and dark colours large changes; all differences larger than the upper limit are shown as full blue and full red, 
respectively. The gradients used for colour coding are also shown separately at the bottom of the figure. B. Enlarged one of the matrices in A, showing the 
comparison between 1XNZ and 2Q96. For clarity, the matrices underwent 2 × 2 binning (maintaining the element with the highest absolute value in the 
respective binning area) before being displayed.
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independently by the hanging-drop vapour-diffusion
method at 18–20°C. Inhibitors (200 mM in DMSO) were
added to concentrated apoenzyme (12 mg/ml, 0.4 mM)
in 10 mM MOPS pH 7.0. Hanging drops contained 3 μl
protein solution mixed with 3 μl reservoir solution. The
reservoir solution consisted of 10–15% PEG 20,000, 0.1
M MES (pH 6.5) and 0.2 mM MnCl2. The concentration
ratio of inhibitor:apoenzyme was 5:1 for 4 and 5 and 10:1
for 6–8, and that of metal:apoenzyme was 5:1.
Data collection and structural refinement
Data were collected on an R-Axis IV imaging plate detector
with a Rigaku rotating anode generator operated at 50 kV
and 100 mA. Images were recorded over 180° in 0.5°
increments at 100 K. Raw reflection data were indexed
and integrated using MOSFLM [43] and merged and
scaled using SCALA in CCP4 [44] with CCP4i interface
[45]. Analysis of the estimated solvent content of each
crystal [46] indicated only one molecule of the enzyme
per asymmetric unit in all cases. The coordinates of our
previously solved structure of E. coli MetAP (PDB code
1XNZ) with ligand, metal ions and water molecules
removed were used as the search model for molecular
replacement using MOLREP [47]. Crystallographic refine-
ment was performed with CNS [48]. The refinement was
monitored using 10% of the reflections set aside for free R
factor analysis throughout the whole refinement process.
Initial refinement started with simulated annealing with a
starting temperature at 4000 K and 25 K drop in tempera-
ture per cycle. The models were refined with iterative
cycles of individual B factor refinement, positional refine-
ment, and manual model building using WinCoot [49].
The Mn(II) atoms were not included in the initial refine-
ment procedure to reduce the model bias in phases and
were then added to the model to the center of the peak in
the Mn(II)-omitted Fobs-Fcalc electron density map. The lig-
and and water molecules were added when the electron
densities shown in 2Fobs-Fcalc and Fobs-Fcalc maps for their
placement were unequivocal. The final 2Fobs-Fcalc maps
showed clear electron density for most of the atoms except
for a few side chains at the molecular surface. The final
models for all of the structures were analyzed using the
program PROCHECK [50], and all have 99.6% of residues
were in the allowed region of their respective Ramachan-
dran plots. The atomic coordinates and structure factors
for the structures have been deposited in the Protein Data
Bank. Statistic parameters in data collection and structural
refinement are shown in Table 1.
Structural analysis
Structures were aligned with PYMOL [51] using the
"align" command, and rmsd values were calculated with
"rms" command after pair-wise alignment. The program
ESCET [35,36] was used to make an objective analysis of
the conformational variability of the eight structures
1XNZ, 2EVM, 2EVC, 2Q92, 2Q93, 2Q94, 2Q95 and
Structural comparison between E. coli MetAP and human MetAPs Figure 7
Structural comparison between E. coli MetAP and human MetAPs. Structure of E. coli MetAP used in the overlays is the one complexed with 4 
and coloured grey. (A) Overlay with human type I MetAP (PDB code 2NQ7) that is coloured cyan for the catalytic domain and blue for the N-terminal 
extension. (B) Overlay with human type II MetAP (PDB code 1B59) that is coloured magenta for the catalytic domain, orange for the N-terminal extension 
and red for the insert. (C) Schematic drawing of the domains in E. coli MetAP and human MetAPs.
catalytic domain
N-terminal extension insert
E. coli  E. coli MetAP MetAP
Human type I MetAP Human type I MetAP
Human type II MetAP Human type II MetAP
C
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2Q96. All drawings for protein structures in the figures
were generated using PYMOL.
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